首页 > 最新文献

Prague medical report最新文献

英文 中文
The Updating and Individualizing of Sleep Hygiene Rules for Non-clinical Adult Populations. 非临床成年人群睡眠卫生规则的更新和个性化。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.14712/23362936.2023.26
Lucie Urbanová, Martina Sebalo Vňuková, Martin Anders, Radek Ptáček, Jitka Bušková

Sleep hygiene is essential for the prevention of somatic and mental disorders, including the prevention of sleep disorders. However, it does not typically address individual differences. The aim of this review is threefold: first, to outline the empirical evidence for particular components of sleep hygiene rules; second, to indicate the importance of individualized sleep hygiene application with regard to the varying degree of validity of sleep hygiene rules in the population; third, to highlight a new field of sleep hygiene, namely light hygiene. PubMed and Google Scholar were used to identify studies that were published between 2007 and 2022. A search was conducted for studies related to sleeping rules topics: sleep regularity, regular exercise, alcohol, caffeine, napping, relaxation and meditation, food intake and light exposure. In applying these sleep hygiene principles, it is essential to pay attention to individual variables such as age, genetic predisposition, health status, and substance (caffeine, alcohol) possible dependence.

睡眠卫生对于预防躯体和精神疾病,包括预防睡眠障碍至关重要。然而,它通常不涉及个体差异。本综述的目的有三:第一,概述睡眠卫生规则特定组成部分的实证证据;第二,针对睡眠卫生规则在人群中不同程度的有效性,指出个性化睡眠卫生应用的重要性;第三,强调睡眠卫生的一个新领域,即光卫生。我们使用 PubMed 和谷歌学术搜索 2007 年至 2022 年间发表的研究。研究搜索了与睡眠规则相关的主题:睡眠规律、定期锻炼、酒精、咖啡因、午睡、放松和冥想、食物摄入和光照。在应用这些睡眠卫生原则时,必须注意个体变量,如年龄、遗传倾向、健康状况和可能依赖的物质(咖啡因、酒精)。
{"title":"The Updating and Individualizing of Sleep Hygiene Rules for Non-clinical Adult Populations.","authors":"Lucie Urbanová, Martina Sebalo Vňuková, Martin Anders, Radek Ptáček, Jitka Bušková","doi":"10.14712/23362936.2023.26","DOIUrl":"https://doi.org/10.14712/23362936.2023.26","url":null,"abstract":"<p><p>Sleep hygiene is essential for the prevention of somatic and mental disorders, including the prevention of sleep disorders. However, it does not typically address individual differences. The aim of this review is threefold: first, to outline the empirical evidence for particular components of sleep hygiene rules; second, to indicate the importance of individualized sleep hygiene application with regard to the varying degree of validity of sleep hygiene rules in the population; third, to highlight a new field of sleep hygiene, namely light hygiene. PubMed and Google Scholar were used to identify studies that were published between 2007 and 2022. A search was conducted for studies related to sleeping rules topics: sleep regularity, regular exercise, alcohol, caffeine, napping, relaxation and meditation, food intake and light exposure. In applying these sleep hygiene principles, it is essential to pay attention to individual variables such as age, genetic predisposition, health status, and substance (caffeine, alcohol) possible dependence.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 4","pages":"329-343"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effects of Nasocomial SARS-CoV-2 Infection after Elective Gastrointestinal Oncologic Procedures: Single Center 30-day Follow-up Results. 选择性胃肠道肿瘤手术后鼻腔SARS-CoV-2感染的影响:单中心30天随访结果
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.14712/23362936.2023.10
Serdar Şenol, Mustafa Kuşak

Although there is extensive debate for the best treatment strategies, limited studies, which reflect the effects of postoperative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on mortality and hospital stay after elective gastrointestinal oncologic procedures were published. In order to contribute to the existing literature, a single-center, retrospective, cross-sectional study, including 301 patients who underwent elective gastrointestinal oncological procedures was planned. Patients' data on sex, age, diagnosis, types of procedures, hospital stay, mortality, and SARS-CoV-2 preoperative screening tests were recorded. Four of them were postponed due to positive preoperative screening for SARS-CoV-2. 395 procedures were performed due to cancer originating from colon (105), rectum (91), stomach (74), periampullar region (16), distal pancreas (4), esophagus (3), retroperitoneum (2), ovary (2), endometrium (1), spleen (1) and small bowel (2). Laparoscopy was the approach of choice for 44 patients (14.7% vs. 85.3%). In the postoperative period, two patients were infected with SARS-CoV-2 and one of them died in the intensive care unit (n=1/2, 50% mortality). Two patients died due to surgical complications unrelated to SARS-CoV-2 (n=2/299, 0.67% mortality) (p<0.01). The mean hospital stay was longer in patients with SARS-CoV-2 infection (21.5 ± 9.1 - 8.2 ± 5.2 days, respectively, p<0.01). 298 patients were safely discharged (99%). During the pandemic elective gastrointestinal oncologic procedures may be safely performed; however, preoperative testing, precautions to minimize contamination should be performed strictly to reduce in-hospital infection rates, since the mortality rate due to SARS-CoV-2 in this setting is particularly high and hospital stay is also significantly increased.

尽管对于最佳治疗策略存在广泛的争论,但反映术后严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)感染对选择性胃肠道肿瘤手术后死亡率和住院时间影响的有限研究已发表。为了对现有文献做出贡献,我们计划进行一项单中心、回顾性、横断面研究,包括301例接受选择性胃肠道肿瘤手术的患者。记录患者的性别、年龄、诊断、手术类型、住院时间、死亡率和SARS-CoV-2术前筛查试验等数据。其中4人因术前SARS-CoV-2筛查阳性而推迟。395例因结肠癌(105例)、直肠(91例)、胃(74例)、壶腹周围(16例)、胰腺远端(4例)、食道(3例)、腹膜后(2例)、卵巢(2例)、子宫内膜(1例)、脾脏(1例)和小肠(2例)而行手术。44例患者选择腹腔镜手术(14.7%对85.3%)。术后2例患者感染SARS-CoV-2,其中1例死亡于重症监护病房(n=1/2,死亡率50%)。2例患者死于与SARS-CoV-2无关的手术并发症(n=2/299,死亡率0.67%)(p<0.01)。SARS-CoV-2感染患者的平均住院时间更长(分别为21.5±9.1 ~ 8.2±5.2 d, p < 0.01)。298例患者安全出院(99%)。在大流行期间,可安全地进行选择性胃肠道肿瘤手术;但是,由于在这种情况下SARS-CoV-2的死亡率特别高,住院时间也显着增加,因此应严格执行术前检测和尽量减少污染的预防措施,以降低院内感染率。
{"title":"The Effects of Nasocomial SARS-CoV-2 Infection after Elective Gastrointestinal Oncologic Procedures: Single Center 30-day Follow-up Results.","authors":"Serdar Şenol,&nbsp;Mustafa Kuşak","doi":"10.14712/23362936.2023.10","DOIUrl":"https://doi.org/10.14712/23362936.2023.10","url":null,"abstract":"<p><p>Although there is extensive debate for the best treatment strategies, limited studies, which reflect the effects of postoperative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on mortality and hospital stay after elective gastrointestinal oncologic procedures were published. In order to contribute to the existing literature, a single-center, retrospective, cross-sectional study, including 301 patients who underwent elective gastrointestinal oncological procedures was planned. Patients' data on sex, age, diagnosis, types of procedures, hospital stay, mortality, and SARS-CoV-2 preoperative screening tests were recorded. Four of them were postponed due to positive preoperative screening for SARS-CoV-2. 395 procedures were performed due to cancer originating from colon (105), rectum (91), stomach (74), periampullar region (16), distal pancreas (4), esophagus (3), retroperitoneum (2), ovary (2), endometrium (1), spleen (1) and small bowel (2). Laparoscopy was the approach of choice for 44 patients (14.7% vs. 85.3%). In the postoperative period, two patients were infected with SARS-CoV-2 and one of them died in the intensive care unit (n=1/2, 50% mortality). Two patients died due to surgical complications unrelated to SARS-CoV-2 (n=2/299, 0.67% mortality) (p&lt;0.01). The mean hospital stay was longer in patients with SARS-CoV-2 infection (21.5 ± 9.1 - 8.2 ± 5.2 days, respectively, p&lt;0.01). 298 patients were safely discharged (99%). During the pandemic elective gastrointestinal oncologic procedures may be safely performed; however, preoperative testing, precautions to minimize contamination should be performed strictly to reduce in-hospital infection rates, since the mortality rate due to SARS-CoV-2 in this setting is particularly high and hospital stay is also significantly increased.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 2","pages":"143-150"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9873569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Convalescent Plasma Therapy on Mortality and Viral Load in Severely Ill Patients with COVID-19. 康复期血浆治疗对新冠肺炎重症患者死亡率和病毒载量的影响。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.14712/23362936.2023.18
Jan Moravec, Martin Müller, Petr Turek, Michal Moravec, Tomáš Nejtek, Roman Zazula

The use of convalescent plasma (CP) appeared to be a promising, easily available and safe way of treatment of severe COVID-19 at the onset of the pandemic in early 2020. Conducted in 2020 and 2021, our study of 52 severely to critically ill COVID-19 patients who received CP plasma as a treatment and of 97 controls found no difference in 30-day or 90-day mortality rates. A significant viral load drop in most patients (4.7 log10 [p<0.001] copies/ml) was observed following CP administration. Retrospective analysis of selected inflammatory markers and immunoglobulins showed higher C-reactive protein levels among the study group, and their decrease on Day 7.

在2020年初新冠肺炎大流行开始时,恢复期血浆(CP)的使用似乎是一种有前途、容易获得和安全的治疗方法。我们在2020年和2021年对52名接受CP血浆治疗的重症至危重症新冠肺炎患者和97名对照组进行的研究发现,30天或90天的死亡率没有差异。CP给药后,在大多数患者中观察到显著的病毒载量下降(4.7log10[p<;0.001]拷贝/ml)。对所选炎症标志物和免疫球蛋白的回顾性分析显示,研究组的C反应蛋白水平较高,并在第7天下降。
{"title":"Effect of Convalescent Plasma Therapy on Mortality and Viral Load in Severely Ill Patients with COVID-19.","authors":"Jan Moravec,&nbsp;Martin Müller,&nbsp;Petr Turek,&nbsp;Michal Moravec,&nbsp;Tomáš Nejtek,&nbsp;Roman Zazula","doi":"10.14712/23362936.2023.18","DOIUrl":"https://doi.org/10.14712/23362936.2023.18","url":null,"abstract":"<p><p>The use of convalescent plasma (CP) appeared to be a promising, easily available and safe way of treatment of severe COVID-19 at the onset of the pandemic in early 2020. Conducted in 2020 and 2021, our study of 52 severely to critically ill COVID-19 patients who received CP plasma as a treatment and of 97 controls found no difference in 30-day or 90-day mortality rates. A significant viral load drop in most patients (4.7 log10 [p&lt;0.001] copies/ml) was observed following CP administration. Retrospective analysis of selected inflammatory markers and immunoglobulins showed higher C-reactive protein levels among the study group, and their decrease on Day 7.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 3","pages":"230-241"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41157532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Predictive Value of Serum Aldosterone Level for Coronary Artery Calcium Score in Patients with Chronic Kidney Disease: A Single-center Study. 血清醛固酮水平对慢性肾脏病患者冠状动脉钙分的预测价值:一项单中心研究。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.14712/23362936.2023.19
Viktor V Semenov, Jizzo R Bosdriesz, Olexandr Kuryata

Patients with chronic kidney disease (CKD) have high cardiovascular risk (CVR), which is often underestimated by conventional tools. The coronary artery calcium score (CACS) significantly improves CVR stratification by conventional tools, but it is often not available in low-resources settings. Aldosterone may be a cheaper alternative to CACS for CVR assessment in CKD patients. The aim was to assess the ability of serum aldosterone level to predict CACS in patients with CKD in comparison to standard predictors. This single-center study included 57 patients aged 40 to 67 years with CKD (estimated glomerular filtration rate [eGFR] ≥45 ml/min) and arterial hypertension. Serum aldosterone, sex, age, body mass index, blood pressure, total cholesterol, eGFR, and proteinuria were used for prediction of CACS>0 Agatston units (AU) and CACS>100 AU. The area under the curve (AUC) with 95% confidence intervals (CI) and the mean Brier scores were examined for predictors of CACS. Aldosterone predicted a CACS>100 AU (AUC = 0.72, 95% CI: 0.56-0.88), but not a CACS>0 AU. Age predicted a CACS>100 AU (AUC = 0.80, 95% CI: 0.67-0.93) and a CACS>0 AU (AUC = 0.75, 95% CI: 0.62-0.89). The addition of aldosterone to age for prediction of a CACS>100 AU improved the mean Brier score, compared to the model with age alone, from 0.16 to 0.14, but not the AUC (0.83, 95% CI: 0.70-0.95). Aldosterone was a significant predictor of a CACS>100 AU in patients with CKD, but aldosterone was not a better predictor than age alone.

慢性肾脏病(CKD)患者具有较高的心血管风险(CVR),而传统工具往往低估了这一风险。冠状动脉钙评分(CACS)通过传统工具显著改善CVR分层,但在低资源环境中通常不可用。对于CKD患者的CVR评估,醛固酮可能是CACS的一种更便宜的替代品。目的是评估血清醛固酮水平与标准预测因子相比预测CKD患者CACS的能力。这项单中心研究包括57名年龄在40至67岁的CKD(估计肾小球滤过率[eGFR]≥45ml/min)和动脉高血压患者。血清醛固酮、性别、年龄、体重指数、血压、总胆固醇、eGFR和蛋白尿用于预测CACS>;0个Agaston单元(AU)和CACS>;100 AU。检查具有95%置信区间(CI)的曲线下面积(AUC)和平均Brier评分,以确定CACS的预测因素。醛固酮预测CACS>;100AU(AUC=0.72,95%CI:0.56-0.88),但不是CACS>;0 AU。年龄预测CACS>;100AU(AUC=0.80、95%CI:0.67-0.93)和CACS>;0 AU(AUC=0.75,95%CI:0.62-0.89)。在预测CACS的年龄中添加醛固酮>;与单独年龄的模型相比,100AU将平均Brier评分从0.16提高到0.14,但AUC没有提高(0.83,95%CI:0.70-0.95)。醛固酮是CACS>;CKD患者为100 AU,但醛固酮并不是比单独年龄更好的预测因素。
{"title":"The Predictive Value of Serum Aldosterone Level for Coronary Artery Calcium Score in Patients with Chronic Kidney Disease: A Single-center Study.","authors":"Viktor V Semenov,&nbsp;Jizzo R Bosdriesz,&nbsp;Olexandr Kuryata","doi":"10.14712/23362936.2023.19","DOIUrl":"https://doi.org/10.14712/23362936.2023.19","url":null,"abstract":"<p><p>Patients with chronic kidney disease (CKD) have high cardiovascular risk (CVR), which is often underestimated by conventional tools. The coronary artery calcium score (CACS) significantly improves CVR stratification by conventional tools, but it is often not available in low-resources settings. Aldosterone may be a cheaper alternative to CACS for CVR assessment in CKD patients. The aim was to assess the ability of serum aldosterone level to predict CACS in patients with CKD in comparison to standard predictors. This single-center study included 57 patients aged 40 to 67 years with CKD (estimated glomerular filtration rate [eGFR] ≥45 ml/min) and arterial hypertension. Serum aldosterone, sex, age, body mass index, blood pressure, total cholesterol, eGFR, and proteinuria were used for prediction of CACS&gt;0 Agatston units (AU) and CACS&gt;100 AU. The area under the curve (AUC) with 95% confidence intervals (CI) and the mean Brier scores were examined for predictors of CACS. Aldosterone predicted a CACS&gt;100 AU (AUC = 0.72, 95% CI: 0.56-0.88), but not a CACS&gt;0 AU. Age predicted a CACS&gt;100 AU (AUC = 0.80, 95% CI: 0.67-0.93) and a CACS&gt;0 AU (AUC = 0.75, 95% CI: 0.62-0.89). The addition of aldosterone to age for prediction of a CACS&gt;100 AU improved the mean Brier score, compared to the model with age alone, from 0.16 to 0.14, but not the AUC (0.83, 95% CI: 0.70-0.95). Aldosterone was a significant predictor of a CACS&gt;100 AU in patients with CKD, but aldosterone was not a better predictor than age alone.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 3","pages":"242-254"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41168403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Retinal Nerve Fibre Layer Thickness and Choroidal Thickness in Parkinson Disease Patients. 帕金森病患者视网膜神经纤维层厚度和脉络膜厚度评估
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.14712/23362936.2023.32
Kwang Sheng Ng, Mohammad Hudzaifah-Nordin, Sathyapriya Tamilarsan Sarah, Wan Hitam Wan-Hazabbah, Abd Halim Sanihah

To evaluate the retinal nerve fibre layer (RNFL) thickness and choroidal thickness (CT) in Parkinson disease (PD) patients. A comparative cross-sectional, hospital-based study. 39 PD and 39 controls were recruited, who were gender and age matched. Subjects that fulfilled the inclusion criteria underwent optical coherence tomography for evaluation of RNFL thickness and choroidal thickness (CT). There was significant reduction of RNFL thickness in average (adjusted mean 88.87 µm vs. 94.82 µm, P=0.001), superior (adjusted mean 110.08 µm vs. 119.10 µm, P=0.002) and temporal (adjusted mean 63.77 µm vs. 70.36 µm, P=0.004) in PD compared to controls. The central subfoveal CT was significantly thinner in PD compared to controls (adjusted mean 271.13 µm vs. 285.10 µm, P=0.003). In PD group, there was significant weak negative correlation between the duration of PD with average RNFL thickness (r=-0.354, P=0.027), moderate negative correlation between the duration of PD with central subfoveal CT (r=-0.493, P=0.001), and weak negative correlation between the stage of PD with central subfoveal CT (r=-0.380, P=0.017). PD group had significant thinner average, superior and temporal RNFL thickness and CT compared to controls.

评估帕金森病(PD)患者的视网膜神经纤维层(RNFL)厚度和脉络膜厚度(CT)。这是一项基于医院的横断面比较研究。共招募了 39 名帕金森病患者和 39 名对照组患者,他们的性别和年龄均匹配。符合纳入标准的受试者接受了光学相干断层扫描,以评估 RNFL 厚度和脉络膜厚度(CT)。与对照组相比,帕金森病患者的 RNFL 平均厚度(调整后的平均值为 88.87 µm 对 94.82 µm,P=0.001)、上部厚度(调整后的平均值为 110.08 µm 对 119.10 µm,P=0.002)和颞部厚度(调整后的平均值为 63.77 µm 对 70.36 µm,P=0.004)均明显减少。与对照组相比,帕金森病患者中央眼底 CT 明显变薄(调整后平均值为 271.13 µm vs. 285.10 µm,P=0.003)。在帕金森氏症组中,帕金森氏症病程与平均 RNFL 厚度呈显著的弱负相关(r=-0.354,P=0.027),帕金森氏症病程与中央眼底 CT 呈中度负相关(r=-0.493,P=0.001),帕金森氏症分期与中央眼底 CT 呈弱负相关(r=-0.380,P=0.017)。与对照组相比,PD 组的平均、上部和颞部 RNFL 厚度和 CT 均明显较薄。
{"title":"Evaluation of Retinal Nerve Fibre Layer Thickness and Choroidal Thickness in Parkinson Disease Patients.","authors":"Kwang Sheng Ng, Mohammad Hudzaifah-Nordin, Sathyapriya Tamilarsan Sarah, Wan Hitam Wan-Hazabbah, Abd Halim Sanihah","doi":"10.14712/23362936.2023.32","DOIUrl":"https://doi.org/10.14712/23362936.2023.32","url":null,"abstract":"<p><p>To evaluate the retinal nerve fibre layer (RNFL) thickness and choroidal thickness (CT) in Parkinson disease (PD) patients. A comparative cross-sectional, hospital-based study. 39 PD and 39 controls were recruited, who were gender and age matched. Subjects that fulfilled the inclusion criteria underwent optical coherence tomography for evaluation of RNFL thickness and choroidal thickness (CT). There was significant reduction of RNFL thickness in average (adjusted mean 88.87 µm vs. 94.82 µm, P=0.001), superior (adjusted mean 110.08 µm vs. 119.10 µm, P=0.002) and temporal (adjusted mean 63.77 µm vs. 70.36 µm, P=0.004) in PD compared to controls. The central subfoveal CT was significantly thinner in PD compared to controls (adjusted mean 271.13 µm vs. 285.10 µm, P=0.003). In PD group, there was significant weak negative correlation between the duration of PD with average RNFL thickness (r=-0.354, P=0.027), moderate negative correlation between the duration of PD with central subfoveal CT (r=-0.493, P=0.001), and weak negative correlation between the stage of PD with central subfoveal CT (r=-0.380, P=0.017). PD group had significant thinner average, superior and temporal RNFL thickness and CT compared to controls.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 4","pages":"421-434"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polypharmacy and Drug Interactions in the COVID-19 Pandemic. COVID-19 大流行中的多重用药和药物相互作用。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.14712/23362936.2023.30
Ricardo Enrique Barcia, Guillermo Alberto Keller, Natalia Bello, Francisco Azzato, Roberto Alejandro Diez, Guido Giunti

The COVID-19 pandemic generated a great impact on health systems. We compared evolution, polypharmacy, and potential drug-drug interactions (P-DDIs) in COVID-19 and non-COVID-19 hospitalizations during first wave of pandemic. Prescriptions for hospitalized patients ≥ 18 years (COVID-19 and non-COVID-19 rooms) between April and September 2020 were included. The computerized medical decision support system SIMDA and the physician order entry system Hdc.DrApp.la were used. Patients in COVID-19 rooms were divided into detectable and non-detectable, according to real-time reverse transcription polymerase chain reaction (RT-PCR). Number of drugs, prescribed on day 1, after day 1, and total; polypharmacy, excessive polypharmacy, and P-DDIs were compared. 1,623 admissions were evaluated: 881 COVID-19, 538 detectable and 343 non-detectable, and 742 non-COVID-19. Mortality was 15% in COVID-19 and 13% in non-COVID-19 (RR [non-COVID-19 vs. COVID-19]: 0.84 [95% CI] [0.66-1.07]). In COVID-19, mortality was 19% in detectable and 9% in non-detectable (RR: 2.07 [1.42-3.00]). Average number of drugs was 4.54/patient (SD ± 3.06) in COVID-19 and 5.92/patient (±3.24) in non-COVID-19 (p<0.001) on day 1 and 5.57/patient (±3.93) in COVID-19 and 9.17/patient (±5.27) in non-COVID-19 (p<0.001) throughout the hospitalization. 45% received polypharmacy in COVID-19 and 62% in non-COVID-19 (RR: 1.38 [1.25-1.51]) and excessive polypharmacy 7% in COVID-19 and 14% in non-COVID-19 (RR: 2.09 [1.54-2.83]). The frequency of total P-DDIs was 0.31/patient (±0.67) in COVID-19 and 0.40/patient (±0.94) in non-COVID-19 (p=0.022). Hospitalizations in the COVID-19 setting are associated with less use of drugs, less polypharmacy and less P-DDIs. Detectable patients had higher mortality.

COVID-19 大流行对医疗系统产生了巨大影响。我们比较了第一波大流行期间 COVID-19 和非 COVID-19 住院病人的用药演变、多重用药和潜在的药物相互作用(P-DDIs)。纳入了 2020 年 4 月至 9 月期间≥ 18 岁住院患者(COVID-19 和非 COVID-19 病房)的处方。使用了计算机化医疗决策支持系统 SIMDA 和医嘱输入系统 Hdc.DrApp.la。根据实时反转录聚合酶链反应(RT-PCR),COVID-19病房的患者分为可检测到和不可检测到两种。比较了第 1 天、第 1 天后的处方药数量和总数;多药、过度多药和 P-DDIs 的情况。共对 1623 例入院患者进行了评估:其中 881 例为 COVID-19,538 例可检测到,343 例无法检测到,742 例为非 COVID-19。COVID-19 死亡率为 15%,非 COVID-19 死亡率为 13%(RR [非 COVID-19 vs. COVID-19]:0.84 [95% CI] [0.66-1.07])。在 COVID-19 中,可检测到的死亡率为 19%,不可检测到的死亡率为 9%(RR:2.07 [1.42-3.00])。住院第 1 天,COVID-19 患者的平均用药次数为 4.54 次/人(SD ± 3.06),非 COVID-19 患者为 5.92 次/人(±3.24)(p<0.001);整个住院期间,COVID-19 患者的平均用药次数为 5.57 次/人(±3.93),非 COVID-19 患者为 9.17 次/人(±5.27)(p<0.001)。在 COVID-19 中,45% 的患者接受了多种药物治疗,而在非 COVID-19 中,62% 的患者接受了多种药物治疗(RR:1.38 [1.25-1.51]);在 COVID-19 中,7% 的患者接受了过度的多种药物治疗,而在非 COVID-19 中,14% 的患者接受了过度的多种药物治疗(RR:2.09 [1.54-2.83])。COVID-19 的总 P-DDIs 频率为 0.31/患者(±0.67),非 COVID-19 为 0.40/患者(±0.94)(P=0.022)。在 COVID-19 环境中住院与用药少、多药疗法少和 P-DDIs 少有关。可检测患者的死亡率较高。
{"title":"Polypharmacy and Drug Interactions in the COVID-19 Pandemic.","authors":"Ricardo Enrique Barcia, Guillermo Alberto Keller, Natalia Bello, Francisco Azzato, Roberto Alejandro Diez, Guido Giunti","doi":"10.14712/23362936.2023.30","DOIUrl":"https://doi.org/10.14712/23362936.2023.30","url":null,"abstract":"<p><p>The COVID-19 pandemic generated a great impact on health systems. We compared evolution, polypharmacy, and potential drug-drug interactions (P-DDIs) in COVID-19 and non-COVID-19 hospitalizations during first wave of pandemic. Prescriptions for hospitalized patients ≥ 18 years (COVID-19 and non-COVID-19 rooms) between April and September 2020 were included. The computerized medical decision support system SIMDA and the physician order entry system Hdc.DrApp.la were used. Patients in COVID-19 rooms were divided into detectable and non-detectable, according to real-time reverse transcription polymerase chain reaction (RT-PCR). Number of drugs, prescribed on day 1, after day 1, and total; polypharmacy, excessive polypharmacy, and P-DDIs were compared. 1,623 admissions were evaluated: 881 COVID-19, 538 detectable and 343 non-detectable, and 742 non-COVID-19. Mortality was 15% in COVID-19 and 13% in non-COVID-19 (RR [non-COVID-19 vs. COVID-19]: 0.84 [95% CI] [0.66-1.07]). In COVID-19, mortality was 19% in detectable and 9% in non-detectable (RR: 2.07 [1.42-3.00]). Average number of drugs was 4.54/patient (SD ± 3.06) in COVID-19 and 5.92/patient (±3.24) in non-COVID-19 (p&lt;0.001) on day 1 and 5.57/patient (±3.93) in COVID-19 and 9.17/patient (±5.27) in non-COVID-19 (p&lt;0.001) throughout the hospitalization. 45% received polypharmacy in COVID-19 and 62% in non-COVID-19 (RR: 1.38 [1.25-1.51]) and excessive polypharmacy 7% in COVID-19 and 14% in non-COVID-19 (RR: 2.09 [1.54-2.83]). The frequency of total P-DDIs was 0.31/patient (±0.67) in COVID-19 and 0.40/patient (±0.94) in non-COVID-19 (p=0.022). Hospitalizations in the COVID-19 setting are associated with less use of drugs, less polypharmacy and less P-DDIs. Detectable patients had higher mortality.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 4","pages":"392-412"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Significance of the Coagulation and Complement Systems in Critical COVID-19 Infection. 凝血和补体系统在COVID-19危重感染中的预后意义
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.14712/23362936.2023.7
Amitabha Ray, Kristen A K Winter, Dayalu S L Naik, Chuku Okorie

Infection with the SARS-CoV-2 virus (COVID-19 disease) can cause a wide range of clinical situations - from an asymptomatic state to fatal outcomes. In cases of serious clinical manifestations, the underlying mechanisms involve a number of immune cells and stromal cells as well as their products such as pro-inflammatory interleukin-6 and tumour necrosis factor-alpha that ultimately cause the cytokine storm. The situation of overproduction of pro-inflammatory cytokines is somewhat similar to, though in a mild form, health conditions in obesity and related metabolic disorders like type-2 diabetes, which are also considered important risk factors for severe illness in COVID-19. Interestingly, neutrophils perhaps play a significant role in this pathogenesis. On the other hand, it is thought that COVID-19-related critical illness is associated with pathological hyperactivity of the complement system and coagulopathy. Although the precise molecular interactions between the complement and coagulation systems are not clear, we observe an intimate cross-talk between these two systems in critically ill COVID-19 patients. It is believed that both of these biological systems are connected with the cytokine storm in severe COVID-19 disease and actively participate in this vicious cycle. In order to hinder the pathological progression of COVID-19, a number of anticoagulation agents and complement inhibitors have been used with varying success. Among these drugs, low molecular weight heparin enoxaparin, factor Xa inhibitor apixaban, and complement C5 inhibitor eculizumab have been commonly used in patients with COVID-19. Our overall experience might help us in the future to tackle any such conditions.

感染SARS-CoV-2病毒(COVID-19疾病)可导致多种临床情况-从无症状状态到致命结果。在严重临床表现的情况下,潜在的机制涉及许多免疫细胞和基质细胞及其产物,如促炎的白细胞介素-6和肿瘤坏死因子- α,最终导致细胞因子风暴。促炎细胞因子过度产生的情况有点类似于肥胖和2型糖尿病等相关代谢紊乱的健康状况,尽管形式较轻,这两种疾病也被认为是COVID-19严重疾病的重要危险因素。有趣的是,中性粒细胞可能在这一发病机制中起重要作用。另一方面,人们认为新冠肺炎相关危重疾病与补体系统病理性亢进和凝血功能障碍有关。尽管补体和凝血系统之间确切的分子相互作用尚不清楚,但我们在COVID-19危重患者中观察到这两个系统之间密切的串扰。我们认为,这两个生物系统都与COVID-19严重疾病的细胞因子风暴有关,并积极参与这种恶性循环。为了阻止COVID-19的病理进展,许多抗凝剂和补体抑制剂已被使用,并取得了不同程度的成功。在这些药物中,低分子肝素依诺肝素、Xa因子抑制剂阿哌沙班、补体C5抑制剂eculizumab已被广泛用于COVID-19患者。我们的总体经验可能会帮助我们在未来解决任何此类问题。
{"title":"Prognostic Significance of the Coagulation and Complement Systems in Critical COVID-19 Infection.","authors":"Amitabha Ray,&nbsp;Kristen A K Winter,&nbsp;Dayalu S L Naik,&nbsp;Chuku Okorie","doi":"10.14712/23362936.2023.7","DOIUrl":"https://doi.org/10.14712/23362936.2023.7","url":null,"abstract":"<p><p>Infection with the SARS-CoV-2 virus (COVID-19 disease) can cause a wide range of clinical situations - from an asymptomatic state to fatal outcomes. In cases of serious clinical manifestations, the underlying mechanisms involve a number of immune cells and stromal cells as well as their products such as pro-inflammatory interleukin-6 and tumour necrosis factor-alpha that ultimately cause the cytokine storm. The situation of overproduction of pro-inflammatory cytokines is somewhat similar to, though in a mild form, health conditions in obesity and related metabolic disorders like type-2 diabetes, which are also considered important risk factors for severe illness in COVID-19. Interestingly, neutrophils perhaps play a significant role in this pathogenesis. On the other hand, it is thought that COVID-19-related critical illness is associated with pathological hyperactivity of the complement system and coagulopathy. Although the precise molecular interactions between the complement and coagulation systems are not clear, we observe an intimate cross-talk between these two systems in critically ill COVID-19 patients. It is believed that both of these biological systems are connected with the cytokine storm in severe COVID-19 disease and actively participate in this vicious cycle. In order to hinder the pathological progression of COVID-19, a number of anticoagulation agents and complement inhibitors have been used with varying success. Among these drugs, low molecular weight heparin enoxaparin, factor Xa inhibitor apixaban, and complement C5 inhibitor eculizumab have been commonly used in patients with COVID-19. Our overall experience might help us in the future to tackle any such conditions.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 2","pages":"77-93"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9873564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Therapeutic Drug Monitoring of Protein Kinase Inhibitors in the Treatment of Non-small Cell Lung Cancer. 蛋白激酶抑制剂治疗非小细胞肺癌癌症的药物监测。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.14712/23362936.2023.16
Judita Staša, Jana Gregorová, Ondřej Slanař, Martin Šíma

Targeted therapy with protein kinase inhibitors (PKIs) represents one of the important treatment options for non-small cell lung cancer (NSCLC). It has contributed to improve patients' survival and quality of life significantly. These anticancer drugs are administrated orally in flat-fixed doses despite the well-known large interpatient pharmacokinetic variability and the possible need for dose individualization. To optimize and individualize dosing of PKIs, and thereby increasing the effectiveness and safety of the treatment, therapeutic drug monitoring (TDM) is the most frequently mentioned method. Unlike other areas of medicine, TDM has been rather exceptional in oncological practise since there is a little evidence or no data for concentration-effect relationships of PKIs. Therefore, the aim of this review is to summarize the pharmacokinetic characteristics of PKIs and provide the evidence supporting the use of TDM for personalised treatment of patients with NSCLC.

蛋白激酶抑制剂(PKIs)的靶向治疗是癌症(NSCLC)的重要治疗选择之一。它有助于显著提高患者的生存率和生活质量。这些抗癌药物是以固定剂量口服给药的,尽管众所周知,患者间的药代动力学变化很大,可能需要剂量个性化。为了优化和个性化PKIs的给药,从而提高治疗的有效性和安全性,治疗药物监测(TDM)是最常提到的方法。与其他医学领域不同,TDM在肿瘤学实践中相当特殊,因为很少有证据或没有数据表明PKIs的浓度-效应关系。因此,本综述的目的是总结PKIs的药代动力学特征,并提供支持TDM用于NSCLC患者个性化治疗的证据。
{"title":"Therapeutic Drug Monitoring of Protein Kinase Inhibitors in the Treatment of Non-small Cell Lung Cancer.","authors":"Judita Staša,&nbsp;Jana Gregorová,&nbsp;Ondřej Slanař,&nbsp;Martin Šíma","doi":"10.14712/23362936.2023.16","DOIUrl":"https://doi.org/10.14712/23362936.2023.16","url":null,"abstract":"<p><p>Targeted therapy with protein kinase inhibitors (PKIs) represents one of the important treatment options for non-small cell lung cancer (NSCLC). It has contributed to improve patients' survival and quality of life significantly. These anticancer drugs are administrated orally in flat-fixed doses despite the well-known large interpatient pharmacokinetic variability and the possible need for dose individualization. To optimize and individualize dosing of PKIs, and thereby increasing the effectiveness and safety of the treatment, therapeutic drug monitoring (TDM) is the most frequently mentioned method. Unlike other areas of medicine, TDM has been rather exceptional in oncological practise since there is a little evidence or no data for concentration-effect relationships of PKIs. Therefore, the aim of this review is to summarize the pharmacokinetic characteristics of PKIs and provide the evidence supporting the use of TDM for personalised treatment of patients with NSCLC.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 3","pages":"199-215"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41156272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complete Denture - Border Molding Technique Using a Laboratory Condensation Silicone Putty: Review. 全口义齿 - 使用实验室冷凝硅胶粘合剂的边缘成型技术:回顾。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.14712/23362936.2023.28
Clóvis Lamartine de Moraes Melo Neto, Daniela Micheline Dos Santos, Marcelo Coelho Goiato

During the fabrication of a complete denture, functional impression is taken. Literature studies show that polydimethylsiloxane (condensation silicone) has not been reported by United States dental schools to perform border molding. Thus, the purpose of this article is to review the functional impression technique when border molding is performed with a laboratory condensation silicone putty.

在制作全口义齿时,需要取功能性印模。文献研究表明,聚二甲基硅氧烷(缩合硅酮)尚未被美国牙科学校报道用于边界成型。因此,本文旨在回顾使用实验室冷凝硅树脂腻子进行边界模塑时的功能性印模技术。
{"title":"Complete Denture - Border Molding Technique Using a Laboratory Condensation Silicone Putty: Review.","authors":"Clóvis Lamartine de Moraes Melo Neto, Daniela Micheline Dos Santos, Marcelo Coelho Goiato","doi":"10.14712/23362936.2023.28","DOIUrl":"https://doi.org/10.14712/23362936.2023.28","url":null,"abstract":"<p><p>During the fabrication of a complete denture, functional impression is taken. Literature studies show that polydimethylsiloxane (condensation silicone) has not been reported by United States dental schools to perform border molding. Thus, the purpose of this article is to review the functional impression technique when border molding is performed with a laboratory condensation silicone putty.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 4","pages":"359-379"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vascular Anatomy and Variations of the Anterior Abdominal Wall - Significance in Abdominal Surgery. 血管解剖和前腹壁的变化-在腹部手术中的意义。
Q4 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.14712/23362936.2023.9
Stoyan Kostov, Svetla Dineva, Yavor Kornovski, Stanislav Slavchev, Yonka Ivanova, Angel Yordanov

Detailed knowledge of the human anatomy is an integral part of every surgical procedure. The majority of surgery related complications are due to a failure to possess appropriate knowledge of human anatomy. However, surgeons pay less attention of the anatomy of the anterior abdominal wall. It is composed of nine abdominal layers, which are composed of fascias, muscles, nerves, and vessels. Many superficial and deep vessels and their anastomoses supply the anterior abdominal wall. Moreover, anatomical variations of these vessels are often presented. Intraoperative and postoperative complications associated with entry and closure of the anterior abdominal wall could compromise the best surgical procedure. Therefore, sound knowledge of the vascular anatomy of the anterior abdominal wall is fundamental and a prerequisite to having a favourable quality of patient care. The purpose of the present article is to describe and delineate the vascular anatomy and variations of the anterior abdominal wall and its application in abdominal surgery. Consequently, the most types of abdominal incisions and laparoscopic accesses will be discussed. Furthermore, the possibility of vessels injury related to different types of incisions and accesses will be outlined in detail. Morphological characteristics and distribution pattern of the vascular system of the anterior abdominal wall is illustrated by using figures either from open surgery, different types of imaging modalities or embalmed cadaveric dissections. Oblique skin incisions in the upper or lower abdomen such as McBurney, Chevron and Kocher are not the topic of the present article.

详细的人体解剖学知识是每一个外科手术不可或缺的一部分。大多数与手术相关的并发症是由于没有掌握适当的人体解剖学知识。然而,外科医生很少关注前腹壁的解剖结构。它由九个腹部层组成,这些层由筋膜、肌肉、神经和血管组成。许多浅血管和深血管及其吻合口供应前腹壁。此外,这些血管的解剖变异也经常出现。前腹壁进入和闭合的术中和术后并发症可能会影响最佳手术方法。因此,对前腹壁血管解剖的良好了解是获得良好的患者护理质量的基础和先决条件。本文的目的是描述和描述前腹壁的血管解剖和变化及其在腹部手术中的应用。因此,大多数类型的腹部切口和腹腔镜进入将被讨论。此外,血管损伤的可能性与不同类型的切口和通道将被详细概述。前腹壁血管系统的形态特征和分布模式通过使用开放手术、不同类型的成像方式或尸体防腐解剖的图像来说明。在上腹部或下腹部的斜皮肤切口,如McBurney, Chevron和Kocher不是本文的主题。
{"title":"Vascular Anatomy and Variations of the Anterior Abdominal Wall - Significance in Abdominal Surgery.","authors":"Stoyan Kostov,&nbsp;Svetla Dineva,&nbsp;Yavor Kornovski,&nbsp;Stanislav Slavchev,&nbsp;Yonka Ivanova,&nbsp;Angel Yordanov","doi":"10.14712/23362936.2023.9","DOIUrl":"https://doi.org/10.14712/23362936.2023.9","url":null,"abstract":"<p><p>Detailed knowledge of the human anatomy is an integral part of every surgical procedure. The majority of surgery related complications are due to a failure to possess appropriate knowledge of human anatomy. However, surgeons pay less attention of the anatomy of the anterior abdominal wall. It is composed of nine abdominal layers, which are composed of fascias, muscles, nerves, and vessels. Many superficial and deep vessels and their anastomoses supply the anterior abdominal wall. Moreover, anatomical variations of these vessels are often presented. Intraoperative and postoperative complications associated with entry and closure of the anterior abdominal wall could compromise the best surgical procedure. Therefore, sound knowledge of the vascular anatomy of the anterior abdominal wall is fundamental and a prerequisite to having a favourable quality of patient care. The purpose of the present article is to describe and delineate the vascular anatomy and variations of the anterior abdominal wall and its application in abdominal surgery. Consequently, the most types of abdominal incisions and laparoscopic accesses will be discussed. Furthermore, the possibility of vessels injury related to different types of incisions and accesses will be outlined in detail. Morphological characteristics and distribution pattern of the vascular system of the anterior abdominal wall is illustrated by using figures either from open surgery, different types of imaging modalities or embalmed cadaveric dissections. Oblique skin incisions in the upper or lower abdomen such as McBurney, Chevron and Kocher are not the topic of the present article.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 2","pages":"108-142"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9873567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Prague medical report
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1